Ignite Creation Date:
2024-05-05 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00526045
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2007-09-05
Brief Title:
Phase I-II Study to Determine the Maximum Tolerated Dose MTD of AUY922 in Advanced Solid Malignancies and Efficacy in HER2 or ER Locally Advanced or Metastatic Breast Cancer Patients
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-07
Start Date Type:
None
Primary Completion Date:
2012-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-04
Completion Date Type:
ACTUAL
First Submit Date:
2007-09-05
First Submit QC Date:
September 5 2007
Study First Post Date:
2007-09-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2020-08-20
Disp First Submit QC Date:
August 20 2020
Disp First Post Date:
2020-08-26
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2020-12-11
Last Update Post Date:
2020-12-17
Last Update Post Date Type:
ACTUAL